Compare BMRA & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | KALA |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.3M |
| IPO Year | 1995 | 2017 |
| Metric | BMRA | KALA |
|---|---|---|
| Price | $2.35 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 196.0K | ★ 376.1K |
| Earning Date | 04-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.81 | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,453,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.45 | $0.07 |
| 52 Week High | $3.21 | $3.96 |
| Indicator | BMRA | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 36.19 |
| Support Level | $2.05 | $0.35 |
| Resistance Level | $2.49 | $0.72 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 39.08 | 15.04 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.